AGORACOM Small-cap Investor Relations Blog

• Company’s common shares will begin trading on the OTCQB® Venture Market (“OTCQB”) today, April 19, 2021 under the current stock symbol “DTMXF”
• Marshall Gunter, CEO of Datametrex AI Limited, “With the Company’s shares now quoted on the OTCQB, it will enhance our visibility and make the Company’s shares available to a much larger group of U.S. investors. “

Toronto, Ontario–(Newsfile Corp. – April 19, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTCQB: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that after a successful application process for the OTCQB® Venture Market (“OTCQB”), the Company’s common shares will begin trading on the OTCQB today, April 19, 2021, at the opening of the market under the current stock symbol “DTMXF” and will remain listed on the TSX Venture Exchange under the ticker symbol “DM”.

Existing U.S. shareholders of Datametrex AI Limited shares, previously quoted on the OTC® Pink Open Market, will now be quoted on the OTCQB without any further action needed.

Marshall Gunter, CEO of Datametrex AI Limited, “With the Company’s shares now quoted on the OTCQB, it will enhance our visibility and make the Company’s shares available to a much larger group of U.S. investors. The quotation on the OTCQB is anticipated to enhance liquidity by providing current and prospective investors with an easily accessible and transparent trading platform where they go and obtain Real Time quotes and market information.”

About OTCQB

The OTCQB® Venture Market is the premier marketplace for entrepreneurial and development stage US and international companies that are committed to providing a high-quality trading and information experience for their US investors. To be eligible, companies must be current in their financial reporting, pass a minimum bid price test, and undergo an annual company verification and management certification process. The OTCQB quality standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors. The ability to have the Company’s shares electronically transferred between brokerages in the US is significantly more convenient and reduces the costs incurred in trading shares. When shares are able to trade electronically, existing investors benefit from greater liquidity and execution speeds, while opening the door to new investors that may have been previously restricted from the Company’s shares.

To read more, click here.

*PCL Antigen has a test sensitivity of 94.29% and the test kits are suitable for point of care tests. No extra equipment is needed.

*They are simple to use, and results are available in 10 minutes. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, especially health care professionals.

Toronto, Ontario–(Newsfile Corp. – March 23, 2021) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex”) is pleased to announce that Heath Canada (“HC”) has approved the PCL Inc.’s (“PCL”) COVID19 AG Rapid test kit (“PCL Antigen”), an antigen point-of-care rapid test device under the Interim Order (“IO”) Respecting the Importation and Sale of Medical Devices for Use in Relation to COVID-19. Datametrex made an application for the PCL Antigen under IO on August 24, 2020, Respecting the Importation and Sale of Medical Devices for use in relation to COVID-19 pursuant to subsection 30.1(1) of the Food and Drugs Act. (link: https://www.canada.ca/en/health-canada/services/drugs-health-products/covid19-industry/medical-devices/authorized/list.html)

According to the manufacturer, PCL Antigen has a test sensitivity of 94.29% and the test kits are suitable for point of care tests. No extra equipment is needed. They are simple to use, and results are available in 10 minutes. Early detection using rapid tests will also provide further protection to Canada’s front-line workers, especially health care professionals.

View the PCL Antigen test manual video by clicking the link: PCL COVID-19 ANTIBODY TEST

The following certifications have been awarded to these PCL Antigen test kits: CE Certificate, Korea KPMG, FIND Listed, UNGM Supplier. Countries includes the EU, 2 countries in the Middle East, Qatar and UAE, India, Russia, 3 countries in Latin America, Guatemala, Ecuador, and Colombia.

“Datametrex has been given another incredible opportunity to sell an additional medical testing device in Canada with the antigen test, with a supplier with outstanding medical devices in PCL. With the highly contagious new variant, and the second wave and possible third wave of COVID-19 in Canada and throughout the world, Datametrex believes an increase in testing capacity is critical to test and protect people,” said Marshall Gunter, CEO of Datametrex AI Limited.

The Company’s ability to fulfill any purchase order for the PCL Rapid test kits is subject to the availability of inventory at the time of order. Due to the extraordinarily high demand for COVID-19 test, there is volatility in the supply chain and available supply may fluctuate on a daily basis. Datametrex anticipates that it will have little, or no upfront costs associated with importing and selling these test kits.

To read more, click here.

• Closed its acquisition of 100% of Concierge Medical Consultants Inc.’s (“Concierge“) issued and outstanding securities (the “Transaction“), pursuant to terms of the share exchange agreement entered into between the Company, Concierge, and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“).
• Concierge is an arm’s length private telehealth and medical concierge services

Toronto, Ontario–(February 11, 2021) –  Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex“) is pleased to announce that further to its press releases dated January 7, 2021 and January 22, 2021, it has closed its acquisition of 100% of Concierge Medical Consultants Inc.’s (“Concierge“) issued and outstanding securities (the “Transaction“), pursuant to terms of the share exchange agreement entered into between the Company, Concierge, and the shareholders of Concierge (the “Concierge Shareholders“) effective January 19, 2021 (the “Definitive Agreement“).

Concierge is an arm’s length private telehealth and medical concierge services company incorporated under the laws of British Columbia.

Terms of the Transaction

Pursuant to the Definitive Agreement, the Company issued 4,411,764 common shares in the capital of the Company (the “Common Shares“) to the Concierge Shareholders at a price of $0.17 per Common Share for an aggregate purchase price of $750,000.

No finder’s fee was payable in connection with the Transaction.

“Hospital ER’s and health practitioners’ clinics are making a strong push for patients who have mild symptoms to use telehealth platforms during the pandemic crisis to help alleviate the strain on emergency rooms and doctors’ offices and I believe this will continue after the pandemic crisis is over,” commented Dr. Jibran Sharif, MD, founder, and CEO of Concierge.

“Telemedicine visits are booming as doctors and patients have adopted social distancing amid the coronavirus crisis, and with the concierge services Dr. Sharif provide, we envision an end to end turnkey solution for patient healthcare,” said Marshall Gunter, CEO of Datametrex, with respect to the closing of the Transaction.

Operations of Concierge Upon Completion of the Transaction

Concierge has become a wholly-owned operating subsidiary of the Company. The Company has appointed Andrew Ryu, Marshall Gunter, and Dr. Jibran Sharif as the new board of the directors of Concierge, and Dr. Sharif is appointed as the President of Concierge following the closing of the Transaction (the “Closing“). In addition, concurrent with the Closing, the Company has entered into a employment agreement with the founder and President of Concierge, Dr. Jibran Sharif. In addition to his role as President of Concierge, Dr. Jibran Sharif will become the Chief Medical Officer of Datametrex.

Read More: https://agoracom.com/ir/DatametrexAI/forums/discussion/topics/755157-datametrex-announces-closing-of-acquisition-with-concierge-medical/messages/2303196#message